Related references
Note: Only part of the references are listed.Crosstalk between Human IgG Isotypes and Murine Effector Cells
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2012)
Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL
Jessica Tatarek et al.
BLOOD (2011)
Impaired development of human Th1 cells in patients with deficient expression of STAT4
Hua-Chen Chang et al.
BLOOD (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Colocalization of the IL-12 receptor and FcγRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-γ
Sri Vidya Kondadasula et al.
BLOOD (2008)
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer
Michael J. Robertson et al.
CLINICAL CANCER RESEARCH (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells
Rossana Trotta et al.
JOURNAL OF IMMUNOLOGY (2008)
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
Dylan Daniel et al.
BLOOD (2007)
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer
Michael J. Robertson et al.
CLINICAL CANCER RESEARCH (2006)
Interleukin-21 enhances NK cell activation in response to antibody-coated targets
Julie M. Roda et al.
JOURNAL OF IMMUNOLOGY (2006)
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells
JM Roda et al.
CANCER RESEARCH (2006)
Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma
MJ Robertson et al.
LEUKEMIA & LYMPHOMA (2005)
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
FJ Hernandez-Ilizaliturri et al.
CLINICAL CANCER RESEARCH (2005)
Impaired interferon-γ production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma
MJ Robertson et al.
BLOOD (2005)
Stabilization of IFN-gamma mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells
A Mavropoulos et al.
BLOOD (2005)
Interferon-γ:: an overview of signals, mechanisms and functions
K Schroder et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-γ and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2
JM Wigginton et al.
JOURNAL OF IMMUNOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Synergy of IL-12 and IL-18 for IFN-γ gene expression:: IL-12-induced STAT4 contributes to IFN-γ promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1
M Nakahira et al.
JOURNAL OF IMMUNOLOGY (2002)
High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma
ZL Jonak et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Differential role of p38 and c-Jun N-terminal kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity
R Trotta et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
